Loading
A phase 2 trial of CFI-400945 run by Canadian Cancer Trials Group, active and no longer recruiting.
Prostate Cancer Biomarker Enrichment and Treatment Selection is a phase 2 interventional study registered as NCT03385655 by Canadian Cancer Trials Group, with 200 participants planned, started 2018-08-01. Conditions recorded: Prostate Cancer. Interventions recorded: Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab and Carboplatin.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/